ICON Medical Imaging Releases MIRA? in an Application Service Provider Model
ICON announced that its Medical Imaging division has made MIRA™, ICON’s medical image review and analysis software, available to clients in an Application Service Provider (ASP) model. ICON Medical Imaging is the first medical imaging provider to offer clients an ASP solution for their image management needs.
MIRA™ is the core application used by ICON Medical Imaging in its daily operations and provides functionality for imaging, image analysis, project management and document management for imaging studies. MIRA™ is also used for central image evaluations and clinical endpoint committees.
With an ASP model, clients can use MIRA™ as a central repository for medical images and have secure, online access to their imaging data anytime, anywhere. The new model also eliminates the costs associated with purchasing and maintaining an image management system in-house and provides a broad platform upon which clients can build their intellectual property framework, including integration with a clinical data repository for a comprehensive view of all clinical trial data components.
The MIRA™ ASP solution offers turn-key cloud hosting services. Each customer is provided with a private cloud, thereby addressing FDA considerations associated with distributed data stores. As the core operational system for ICON Medical Imaging, MIRA™ meets associated industry guidelines and has passed every client and FDA study audit since its first release in 2005.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
